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Abstract
Background To evaluate changes in retinal and choroidal thick-
ness changes after three intravitreal ranibizumab (IVR) in-
jections for polypoidal choroidal vasculopathy (PCV) using
enhanced depth-imaging-optical coherence tomography
(EDI-OCT).
Methods In this retrospective, observational case series,
EDI-OCT was used to measure changes in choroidal thick-
ness at nine points in a lattice shape in the macula before and
after introductory-stage IVR.
Results Choroidal thickness was decreased at all nine points
in the lattice shape, but was significantly decreased only at
the fovea.
Conclusion The subfoveal choroidal thickness may be re-
duced by introductory-stage IVR in patients with PCV. In
particular, choroidal thickness at the fovea was reduced
during the early stage of treatment.
Keywords Choroidal thickness . Polypoidal choroidal
vasculopathy . Enhanced depth imaging . Optical coherence
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Introduction
Exudative age-related macular degeneration (AMD) is a
disease in which neovessels and vascular anomalies form
in the macula. Polypoidal choroidal vasculopathy (PCV) of
subtype of AMD has neovessels and vascular anomalies in
not only the fovea but also the macula. Optical coherence
tomography (OCT) of the fovea alone cannot identify changes
at lesion sites. Among the many OCT methods of assessing
AMD are enhanced depth-imaging-OCT (EDI-OCT) [1–5].
Although several studies have evaluated subfoveal choroidal
thickness in patients with AMD, subfoveal assessment alone
is insufficient in patients with PCV, a disease that originates in
both the subfoveal and extrafoveal choroid and later spreads
throughout the choroid. Since PCV involves the formation of
network vessels and accompanying polypoidal vessels, anal-
ysis of both subfoveal and extrafoveal choroidal thickness is
necessary, especially in assessing treatment outcomes.
In contrast to standard OCT imaging, EDI-OCT uses long
wavelengths to achieve high penetration [6]. With EDI-OCT,
the retinal pigment epithelium is highly permeable, and high
resolution is achieved at close to optimal distance from the
light source. The Heidelberg Engineering Spectralis OCT uti-
lizes these characteristics to allow OCT to be applied at even
closer distances. This puts the choroid at the optimal distance
from the light source, produces an upside-down image, and
projects the choroid clearly. Thus, in a normal eye, the choroid
will be the thickest at the fovea, thicker temporal to the fovea
than nasal, and thicker superior to the fovea than inferior.
Choroidal thickness has been found to decrease with age and
to be inversely related to the axial length of the eye. Moreover,
a thinner choroid has been associated with refractive error
tending more towards myopia [7–12].
Ranibizumab (Lucentis®, Novartis) is a humanized mono-
clonal antibody fragment that binds to vascular endothelial
growth factor (VEGF) isoforms and has been approved for the
treatment of patients with wet AMD [13, 14]. We retrospec-
tively analyzed choroidal thickness at nine sites in the macula
using EDI-OCT before and after the introductory stage of
intravitreal ranibizumab (0.5 mg) therapy (IVR), performed
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once per month for three consecutive months, in patients with
PCV [14].
We investigated in which part the biggest change of
choroidal thickness of macula area after ranibizumab therapy
would appear in PCV.
Materials and methods
This study is a retrospective and observational case series.
This study adhered to the tenets of the Declaration of Hel-
sinki and was given exempt status by the Yokohama City
University institutional review board. Here, we examine
medical data that was previously collected. Because this
study was retrospective and all data were de-identified, there
was no risk incurred by subjects who included their private
health information in analyses.
All subjects were examined in an outpatient setting at the
Yokohama City University Eye Clinic. Choroidal thickness
was measured in 45 eyes in 43 subjects (mean age: 70.4±-
8.0 years), including 33 eyes in 31 males and 12 eyes in 12
females, who had been diagnosed with PCVand who had not
undergone IVR treatment for at least 1 year. There was no
patient who underwent treatment for PCV other than IVR.
Patients with diseases that affect choroidal thickness, includ-
ing high myopia and uveitis, were excluded. EDI-OCT was
performed using a Spectralis (Heidelberg Engineering) OCT
before and after the introductory stage of IVR, consisting of
IVRs performed once monthly for 3 months.
Choroidal thickness, defined as the distance from the inferior
margin of the retinal pigment epithelium to the choroid/sclera
border, was measured at nine sites in the macula. These nine
sites formed a lattice shape with the fovea at the center, with
pairs of sites 1,200 μm apart (Fig. 1). These nine sites included
points superior-nasal, superior, superior-temporal, mid-nasal,
central, mid-temporal, inferior-nasal, inferior, and inferior-
temporal to the fovea. Changes in choroidal thickness were
calculated from before to after IVR. One unblinded investigator
and two blinded investigators to treatment status determined the
choroidal thickness. The average outcome of three measure-
ments of the choroidal thickness was used for calculation. None
of the patients experienced any complications, such as vitreous
hemorrhage and endophthalmitis.
Results
No patient dropped out during the introductory stage of IVR.
Pre- and post-IVR thicknesses and changes in thickness are
shown in the Table 1. Choroidal thickness was decreased at
Fig. 1 The nine measurement sites of choroidal thickness using cross-
sectional images of enhanced depth-imaging-optical coherence tomog-
raphy. This photograph is obtained in volume mode of Spectralis OCT
Table 1 Mean ± SD foveal
thickness at nine macular sites
before and after introductory-
stage IVR and mean change in
thickness in 45 eyes of 43 pa-
tients with PCV
Macular site Pre-IVR thickness (μm) Post-IVR thickness (μm) Change in thickness
(μm/month)
Superior-nasal 223.6±64.5 210.8±70.6 0.96
Superior 240.7±67.3 231.9±84.5 0.97
Superior-temporal 225.2±60.2 207.5±67.7 0.94
Mid-nasal 218.0±57.8 190.9±64.8 0.90
Central fovea 243.2±65.6 213.2±74.5 0.89 (p=0.03)
Mid-temporal 226.9±57.1 209.1±72.9 0.93
Inferior nasal 216.0±61.9 202.3±69.9 0.94
Inferior 233.4±76.4 221.1±90.9 0.94
Inferior temporal 218.1±69.4 201.4±73.9 0.92
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all sites, with significant decreases in the central fovea
(p=0.03; Table 1). The mean rate of change at the nine sites
was −0.93±0.03 μm/month. In addition, the pre-to-post IVR
introduction stage rate of change at the central fovea was
found to be statistically significant on the Mann-Whitney U-
test analysis. In the IVR treatment for PCV, post-treatment
choroidal thickness was decreased at all nine measurement
sites compared to pre-treatment choroidal thickness. In ad-
dition, a statistically significant decrease was observed in
subfoveal choroidal thickness. These results suggest the
possibility that choroidal thickness throughout the macula
is reduced from pre- to post-IVR introduction-stage therapy
in PCV.
We showed the representative case of PCV whose cho-
roidal thickness at the fovea was reduced during the early
stage of IVR treatment.
A 68-year-old female became aware of distorted vision in
her right eye; a fundoscopic examination revealed an orange-
red protrusion. The patient had polypoidal vessels in the
vicinity of the site superior to the fovea, and PED was
observed using fluorescein (Fig. 2a) and using indocyanine
green (Fig. 2b). She was diagnosed with PCV based on a
contrast study and was treated with three consecutive
Fig. 2 a Angiographic findings using fluorescein before intravitreal
ranibizumab therapy in Case b Angiographic findings using indocya-
nine green before intravitreal ranibizumab therapy in Case. Yellow lines
indicate where choroidal thickness was measured using enhanced
depth-imaging-optical coherence tomography
Fig. 3 a, b, c Choroidal thickness measurements on enhanced depth-
imaging-optical coherence tomography images before intravitreal
ranibizumab therapy in Case. Labels represent the choroidal thickness
(in μm) at the location indicated by the arrowheads. The superior
measurement line (Fig. 3a), central measurement line (Fig. 3b), and
inferior measurement lines (Fig. 3c) are shown. The broken line shows
the posterior border of the choroid
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monthly IVRs. Prior to treatment, the choroidal thicknesses
at the superior-nasal, superior, and superior-temporal sites
were 219 μm, 275 μm, and 255 μm (Fig. 3a); mid-nasal,
central fovea, and mid-temporal sites were 151 μm, 182 μm,
and 202 μm (Fig. 3b); inferior-nasal, inferior, and inferior-
temporal sites were 141 μm, 166 μm, and 189 μm (Fig. 3c).
A contrast study following the three IVRs found reduced
activity at the lesion site observed using fluorescein (Fig. 4a)
and using indocyanine green (Fig. 4b). The choroidal thick-
nesses at the superior-nasal, superior, and superior-temporal
sites were 206 μm, 265 μm, and 237 μm (Fig. 5a); mid-nasal,
central fovea, and mid-temporal sites were 146 μm, 169 μm,
and 196 μm (Fig. 5b); inferior-nasal, inferior, and inferior-
temporal sites were 133 μm, 158 μm, and 171 μm (Fig. 5c).
The pre-treatment visual acuity in her right eye was 20/50,
while her post-treatment visual acuity improved to 20/25.
Discussion
We have studied changes in choroidal thickness occurring
after introductory IVR in patients with PCV using EDI-OCT.
The average choroid thickness decreased at all nine sites, with
the rate of change of choroidal thickness ranging from −0.89
to −0.97 μm/month. The highest rate of change was at the
Fig. 4 a Angiographic findings using fluorescein after intravitreal
ranibizumab therapy in Case b Angiographic findings using indocya-
nine green after intravitreal ranibizumab therapy in Case. Yellow lines
indicate where choroidal thickness was measured using enhanced
depth-imaging-optical coherence tomography
Fig. 5 a, b, c Enhanced depth-imaging-optical coherence tomography
images after intravitreal ranibizumab therapy in Case. Labels represent
the choroidal thickness (in μm) at the location indicated by the arrow-
heads. The superior measurement line (Fig. 5a), central measurement
line (Fig. 5b), and inferior measurement lines (Fig. 5c) are shown. The
broken line shows the posterior border of the choroid
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central fovea, with this change being statistically significant.
These findings indicate that introductory IVR treatment con-
tributed to decreased subfoveal choroidal thickness.
Three subtypes of AMD have been described, typical
AMD, retinal angiomatous proliferation (RAP), and PCV.
PCV spreads throughout the choroid, with network and
polypoidal vessels present in the choroid. Reduced dilation
of medium and large choroidal vessels, as well as reduced
enlargement of the choroidal stroma, may have contributed
to the change in choroidal thickness we observed.
We analyzed the change in the choroidal thickness that was
found after introductory IVR treatment. Patients require differ-
ent numbers of IVR administrations to stabilize PCV; there-
fore, comparisons at PCV stabilization would have involved
large differences in ranibizumab doses among patients. Rather
than comparing choroids that had stabilized after the end of the
treatment, we assessed choroids after 3 IVRs, when doses and
administration periods were the same for all patients.
The choroid supplies oxygen and energy to the outer layers
of the retina and dissipates any heat generated by retinal
activity. Choroid activity is thought to be higher in the macula,
particularly in and near the fovea, than elsewhere in the retina.
PCV results in edema throughout the macular choroid. IVR is
thought to promote partial recovery of choroidal function,
dilate choroidal vessels, and improve stromal edema. In par-
ticular, introductory IVR has been found to strongly improve
stromal edema in and near the fovea, where physiological
activity is high. We could not determine whether the decrease
in choroidal thickness we observed improved visual function
[15]. However, the reduction of choroidal enlargement indi-
cates an indirect suppression of disease activity; therefore, the
recovery of normal choroidal thickness would likely have
positive effects on visual function. Furthermore, introductory
IVR has been shown to suppress the release of cytokines at
lesion sites in the choroid, thereby reducing choroidal thick-
ness regardless of whether abnormal vascular networks or
polypoidal vessels were present.
Although we evaluated the effects of introductory IVR on
choroidal thickness, many of the patients we assessed went
on to receive chronic-stage IVR treatment. It is therefore
necessary to conduct long-term studies to confirm whether
the improvements in choroidal thickness in and near the
fovea were maintained. Moreover, future studies should
assess the effects of introductory-stage IVR on choroidal
thickness in patients with AMD and RAP and to investigate
whether changes in choroidal thickness are observed regard-
less of lesion location.
We detected the biggest change of choroidal thickness after
ranibizumab therapy was appeared in fovea of macula area.
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